Understanding CARdiac Events in Breast Cancer - Pilot Cardio-Oncology Assessment and Surveillance Pathway for Breast Cancer Patients

Status: Recruiting
Location: See all (4) locations...
Study Type: Observational
SUMMARY

In Ireland, over 3,000 patients are diagnosed with breast cancer annually, and 1 in 9 Irish women will be diagnosed with breast cancer in their lifetime. There is evidence that female breast cancer survivors are more likely to die of cardiovascular disease than their age-matched counterparts. This research is focused on evaluating pathways for identifying, managing, and overcoming side effects of cancer therapies that can negatively impact quality-of-life and overall outcomes for women during and after cancer treatment. The Cardio-oncology research team at GUH plan to capitalize on their expertise in both cancer care and cardiology to develop a care pathway for cancer patients who are at increased risk of developing heart disease.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:

• Women aged ≥ 18 years

• Ability to read and understand English

• Breast Cancer Stage I- III planned to receive systemic chemotherapy

Locations
Other Locations
Ireland
Galway Clinic
RECRUITING
Galway
Galway University Hospital
RECRUITING
Galway
Mayo University Hospital
RECRUITING
Mayo
Sligo General Hospital
RECRUITING
Sligo
Contact Information
Primary
Osama Soliman, MBBCh, PhD
osama.soliman@nuigalway.ie
+35391493781
Backup
Aoife Lowery, MBBCh, PhD
aoife.lowery@nuigalway.ie
Time Frame
Start Date: 2023-01-14
Estimated Completion Date: 2026-07
Participants
Target number of participants: 100
Treatments
Anthracycline based chemotehrapy low and moderate risk
Patients recieving anthracycline based chemotherapy who fall into the low and moderate risk category following HFA - ICOS cardiac risk assessment as per the European Society of Cardiology Guidelines.~These patients are monitored taking biobank bloods, bloods, ecg and cardiac echo as per the European Society of Cardiology guidelines whilst receiving chemotherapy.
Anthracycline based chemotherapy - high and very high risk
Patients who recieving anthracycline who fall into the high and very high risk category following HFA - ICOS cardiac risk assessment as per the European Society of Cardiology Guidelines.~These patients are monitored taking biobank bloods, bloods, ecg and cardiac echo as per the European Society of Cardiology guidelines whilst receiving chemotherapy.
Herceptin targeted therapy - low and moderate risk
Patients who are recieving herceptin that fall into the low and moderate risk category following HFA-ICOS cardiac risk assessment as per the European Society of Cardiology Guidelines. These patients are monitored taking biobank bloods, bloods, ecg and cardiac echo as per the European Society of Cardiology Guidelines.
Herceptin targeted therapy - high and very high risk
Patients who are recieving herceptin that fall into the high and very high risk category following HFA-ICOS cardiac risk assessment as per the European Society of Cardiology Guidelines. These patients are monitored taking biobank bloods, bloods, ecg and cardiac echo as per the European Society of Cardiology Guidelines.
Sponsors
Collaborators: CORRIB Research Centre for Advanced Imaging and Core Lab, Galway, Ireland, HRB Clinical Research Facility Galway
Leads: National University of Ireland, Galway, Ireland

This content was sourced from clinicaltrials.gov